Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100291 | 1.00 | HSD11B1 (0.45) | HSD11B1OPRM1PSEN1PSEN2APH1B | |
| SCHEMBL4294143 | 0.83 | HSD11B1 (0.45) | HSD11B1OPRM1PSEN1PSEN2APH1B | |
| SCHEMBL4298912 | 0.83 | HSD11B1 (0.45) | HSD11B1OPRM1PSEN1PSEN2APH1B | |
| SCHEMBL8038060 | 0.83 | HSD11B1 (0.51) | HSD11B1OPRM1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14144468 | 0.82 | HSD11B1 (0.43) | HSD11B1OPRM1PSEN1PSEN2APH1B | |
| SCHEMBL8030808 | 0.80 | HSD11B1 (0.46) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4296589 | 0.80 | HSD11B1 (0.46) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28775897 | 0.80 | HSD11B1 (0.46) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4678027 | 0.79 | ENO1 (0.46) | HSD11B1OPRM1PSEN1PSEN2APH1B | |
| SCHEMBL4087160 | 0.79 | ENO1 (0.46) | HSD11B1OPRM1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1950211-A1 | PROCESS FOR PRODUCTION OF CINNAMAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | CBR1, H1-0, CBR3 | HSD11B1 495/4885OPRM1 621/4885PSEN1 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.